"A Cytokine Working Group phase II study of temozolomide (TMZ), thalidomide (THAL) and whole brain radiation therapy (WBRT) for patients with brain metastases from melanoma" by M. B. Atkins

Selected Works of Walter J. Urba, MD, PhD

Article

A Cytokine Working Group phase II study of temozolomide (TMZ), thalidomide (THAL) and whole brain radiation therapy (WBRT) for patients with brain metastases from melanoma

Journal of Clinical Oncology (2005)

M. B. Atkins, Indiana University
J. Sosman
S. Agarwala, University of Pittsburgh
T. Logan, Loyola University Chicago
J. Clark, Loyola University Chicago
M. Ernstoff, Loyola University Chicago
D. Lawson, Emory University
J. Dutcher, New York Medical College
G. Weiss, University of Texas Health Science Center at San Antonio
W. Urba, Providence Portland Medical Center
K. Margolin, Seattle Cancer Care Alliance

Link

Disciplines

Publication Date

January 6, 2005

DOI

10.1200/jco.2005.23.16_suppl.7552

Citation Information

M. B. Atkins, J. Sosman, S. Agarwala, T. Logan, et al.. "A Cytokine Working Group phase II study of temozolomide (TMZ), thalidomide (THAL) and whole brain radiation therapy (WBRT) for patients with brain metastases from melanoma" Journal of Clinical Oncology Vol. 23 (2005) p. 7552 - 7552
Available at: http://works.bepress.com/walter-urba/199/